The role of fibroblast growth factor 21 (FGF21) In Metabolic Associated Fatty Liver Disease

The role of fibroblast growth factor 21 (FGF21) In Metabolic Associated Fatty Liver Disease

Metabolic associated fatty liver disease (MAFLD) is diagnosed when patients have hepatic steatosis in the context of presence of one or more of the following metabolic conditions: obesity/overweight, diabetes, and metabolic dysregulation either alone or in combination

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:NeuroQuantology 2022-01, Vol.20 (16), p.2760
Hauptverfasser: Asmaa Salah Mohammed Abd El Fattah, Mahmoud Mahmoud Mohammed Abuleneen Khattab, Gamal Elsayed Mohammed Shiha, Hosney Sayed Abdel Ghany, Lamiaa Hamdy Aly
Format: Artikel
Sprache:eng
Schlagworte:
Diabetes
Fibroblasts
Growth factors
Hepatitis
Hepatology
Insulin resistance
Internal medicine
Kidney diseases
Liver
Liver cancer
Liver cirrhosis
Liver diseases
Medicine
Metabolism
Obesity
Overweight
Pathogenesis
Plasma
Triglycerides
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Metabolic associated fatty liver disease (MAFLD) is diagnosed when patients have hepatic steatosis in the context of presence of one or more of the following metabolic conditions: obesity/overweight, diabetes, and metabolic dysregulation either alone or in combination
ISSN:1303-5150
DOI:10.48047/NQ.2022.20.16.NQ880277